Findings

What do systematic reviews say?

476 questions · 488 findings · 43 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 134 · 27.5%GRADE not reported 21 · 4.3%Very low 91 · 18.6%Low 135 · 27.7%Moderate 78 · 16%High 29 · 5.9%

Metformin vs dipeptidyl‐peptidase 4 inhibitors

Non‐fatal MI

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 543 participants
Very low

Metformin vs dipeptidyl‐peptidase 4 inhibitors

Non‐fatal stroke

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 543 participants
Very low

Metformin vs dipeptidyl‐peptidase 4 inhibitors

End‐stage renal disease

The review found no eligible studies for this question.

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metformin vs glucagon like peptide‐1 analogues

All‐cause mortality

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 807 participants
Very low

Metformin vs insulin

Quality of life Short‐Form 36 health survey (SF‐36)

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 91 participants
Very low

Metformin vs glucagon like peptide‐1 analogues

SAEs

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 807 participants
Very low

Metformin vs glucagon like peptide‐1 analogues

Health‐related quality of life

The review found no eligible studies for this question.

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metformin vs glucagon like peptide‐1 analogues

Cardiovascular mortality

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 807 participants
Very low

Metformin vs glucagon like peptide‐1 analogues

Non‐fatal MI

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 807 participants
Very low

Metformin vs glucagon like peptide‐1 analogues

Non‐fatal stroke

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 807 participants
Very low

Metformin vs glucagon like peptide‐1 analogues

End‐stage renal disease

The review found no eligible studies for this question.

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metformin vs meglitinides

All‐cause mortality

The review found no eligible studies for this question.

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metformin vs meglitinides

Serious adverse events

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 112 participants
GRADE not reported

Metformin vs meglitinides

Health‐related quality of life

The review found no eligible studies for this question.

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metformin vs meglitinides

Cardiovascular mortality

The review found no eligible studies for this question.

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metformin vs insulin

Cardiovascular mortality

The review found no eligible studies for this question.

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metformin vs meglitinides

Non‐fatal MI

The review found no eligible studies for this question.

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metformin vs meglitinides

Non‐fatal stroke

The review found no eligible studies for this question.

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metformin vs meglitinides

End‐stage renal disease

The review found no eligible studies for this question.

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Metformin vs insulin

Non‐fatal MI

The review found no eligible studies for this question.

1 finding from 1 review

Metformin monotherapy for adults with type 2 diabetes mellitus 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found